In 2010, Kristján Jóhannsson purchased Parlogis ehf. (company registration 6212002320) from the nationalized Landsbankinn for ISK 250 million. Before the sale, the bank had already converted over ISK 1 billion in company debts into equity. Gunnar Helgi Hálfdánarson, the bank's chairman at the time, was described in the newspaper DV as an 'old friend' of the buyer. The bank never denied this connection. Three years prior, Kristján and his son Jóhann Ingi Kristjánsson had taken over Icepharma hf. (company registration 6202696119), Iceland's oldest pharmaceutical importer, founded in 1969. By acquiring Parlogis — Iceland's pharmaceutical distribution arm — the family now controlled both the import and distribution of pharmaceuticals in Iceland. The Competition Authority (Samkeppniseftirlitið) approved the merger with no conditions in Decision 29/2010, classifying it as a vertical integration. Inga Rósa Guðmundsdóttir, daughter-in-law of Kristján and wife of Jóhann Ingi, was listed as a co-owner of Akurey ehf., the holding company involved in the acquisition, while she worked as a pharmacist at Lyfjastofnun — the Icelandic Medicines Agency that regulates the pharmaceutical sector. She later divested her ownership stake, citing potential conflicts of interest. According to data from Iceland's open government spending registry (Opnir reikningar), state institutions have made 1,020 payments totaling ISK 16,175,037,066 to Parlogis between December 2018 and March 2026. Landspítali National Hospital accounts for 98.9% of these payments — making Parlogis the single largest vendor to Iceland's national hospital at 8.5% of its recorded spending. Annual payments: 2019: ISK 1.91 billion; 2020: ISK 1.90 billion; 2021: ISK 2.44 billion; 2022: ISK 1.95 billion; 2023: ISK 1.42 billion; 2024: ISK 3.14 billion; 2025: ISK 2.66 billion. Parlogis revenue grew from ISK 14 billion in 2019 to ISK 21.5 billion in 2025. In 2020, during the COVID-19 pandemic, profit jumped 18-fold from ISK 6 million to ISK 108 million. By 2025, profit had fallen 84% to ISK 13.5 million, while cash reserves dropped from ISK 486 million to ISK 28 million. Despite this, ownership proposed a dividend of ISK 400 million for 2025 — higher than the ISK 350 million paid in 2024. The family also holds a 49% stake in Arnarland ehf., a 9-hectare development site in Garðabær, alongside Arion bank (51%). Ingunn Svala Leifsdóttir sat simultaneously on the boards of Kvika investment bank and Parlogis in 2022–2023. Margrét Guðmundsdóttir, who holds 19.1% of the parent company Lyng ehf. and served as CEO of Icepharma for 11 years (2005–2016), is now deputy chair of Eimskip hf. The parent company Lyng ehf. also holds stakes in Good Good ehf. (34.7%, sugar-free food brand), Greenfit ehf. (38%, health clinic), and Sunna frjósemi ehf. (43%, fertility clinic), which collectively generated losses of ISK 298.7 million in 2025. Parlogis is Iceland's largest wholesaler by revenue and the dominant supplier of pharmaceuticals and medical goods to the Icelandic state health system. The company was originally founded as Lyfjadreifing ehf. in 2000. Sources: Annual reports of Parlogis ehf. 2021–2025; Annual reports of Eignarhaldsfélagið Lyng ehf. 2024–2025; Iceland open government spending registry (Opnir reikningar) 2018–2026; DV newspaper August 13, 2010; Competition Authority Decision 29/2010.